Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18634104 | 0.86 | POLB (0.36) | POLBLMNA | |
| SCHEMBL18634107 | 0.86 | CYP19A1 (0.40) | POLBCHRM1 | |
| SCHEMBL17883599 | 0.84 | CHRM2 (0.41) | POLBSIGMAR1GAADRD3CHRM2 | |
| SCHEMBL18634150 | 0.82 | NOD1 (0.35) | POLB | |
| SCHEMBL18634027 | 0.82 | ALDH1A1 (0.42) | POLBMC4RLMNADRD3CHRM2 | |
| SCHEMBL18634022 | 0.81 | MC4R (0.57) | POLBSIGMAR1MC4RLMNADRD3 | |
| SCHEMBL2734403 | 0.81 | NPC1 (0.37) | POLBLMNAHPGDDRD3CHRM2 | |
| SCHEMBL18634243 | 0.80 | HRH3 (0.51) | LMNA | |
| SCHEMBL3714616 | 0.79 | ALDH1A1 (0.39) | POLBHPGDDRD3CHRM2CHRM4 | |
| SCHEMBL10760096 | 0.79 | NPC1 (0.36) | POLBSIGMAR1GAAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885718-B1 | FLUORESCENT CHEMICAL COMPOUNDS HAVING HIGH SELECTIVITY FOR DOUBLE STRANDED DNA, AND METHODS FOR THEIR USE | LIFE TECHNOLOGIES CORP (US) | 2017-03-15 | — | — | EP | disclosed |
| US-7598385-B2 | Asymmetric cyanine fluorescent dyes | SHENZHEN MINDRAY BIOMEDICAL ELECTRONICS CO., LTD. (CN) | 2009-10-06 | — | — | US | disclosed |
| US-20090017441-A1 | Reacting unsubstituted or substituted 2-methylbenzothiazole, 2-methylbenzooxazole or 2,3,3-trimethyl-3H-indoline with substituted or unsubstituted benzylhalide, forming 4-methylquinoline quaternary ammonium salt intermediates, condensing with N,N'-diphenylformamidine; for staining nucleic acids | SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. (CN) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017441-A1 | Reacting unsubstituted or substituted 2-methylbenzothiazole, 2-methylbenzooxazole or 2,3,3-trimethyl-3H-indoline with substituted or unsubstituted benzylhalide, forming 4-methylquinoline quaternary ammonium salt intermediates, condensing with N,N'-diphenylformamidine; for staining nucleic acids | RCC1, DNMT3A, H1-4 | POLB 349/4885SIGMAR1 1475/4885MC4R 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.